Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology

摘要: The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic target for patients with non-small-cell lung cancer (NSCLC). However, despite its almost universal presence in NSCLC tumors, inhibition of EGFR resulted significant tumor regressions only 10% to 20% patients. Several investigations over the last 12 months have uncovered somatic mutations that underlie sensitivity inhibitors. tumors and cell lines are exquisitely sensitive tyrosine kinase inhibitors (TKIs), erlotinib gefitinib, biologically distinct from other forms NSCLC. Somatic found more frequently adenocarcinomas, nonsmokers, Asian ethnicity, females. mutation detection is now becoming clinically available being incorporated into clinical treatment decisions design future trials. Mutations K-ras, a mediator signaling, mutually exclusive mutations, associated resistance TKIs. In addition, secondary conferring TKIs, primary once beginning be identified. frequency their impact on biology, treatment, trial design, well methods limitations detection, will reviewed.